Medtronic Receives FDA Approval For Next Generation Professional Continuous Glucose Monitoring
Medtronic, Inc. (NYSE:MDT) today announced the Food and Drug
Administration (FDA) approval of iPro
®2, a next generation
Professional continuous glucose monitoring (CGM) system and the latest
in a series of recent...
About CGM Systems A Professional CGM system, such as iPro2, is a clinician-owned device that collects glucose data without patient interaction for retrospective review. A Personal CGM system is a patient-owned device that displays real-time glucose data; it is available in a standalone CGM device – the Guardian ® REAL-Time System – or as part of the Medtronic integrated insulin system, the MiniMed Paradigm ® REAL-Time Revel ™ System, which combines CGM with insulin pump therapy. About the Diabetes Business at Medtronic The Diabetes business at Medtronic ( www.medtronicdiabetes.com) is the world leader in advanced diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management software, as well as world-class, 24/7 expert consumer and professional service and support. About Medtronic Medtronic, Inc. ( www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.